Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

NCT07124858 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer (CRC)
Antineoplastic Agents, Immunological
VEGFR-TKI

Interventions

DRUG: Fruquintinib

Sponsor

Federation Francophone de Cancerologie Digestive